A New study out of Israel for the treatment of Autistic children using medical marijuana was released last month. Although the study says it used Cannabidiol, the study used an oral oil containing both CBD and THC at a ratio of 20:1. It is sad that the USA cannot study marijuana for autism and that we have to rely upon other countries to do the research. This is the main reason why people have taken it into their own hands to legalize medical marijuana because the FDA and DEA refuse to allow cannabis to be studied for benefits of medical conditions.
Parents who have been able to treat their autistic children with medical cannabis already knew what the results of trials would be. When the child's behaviors and communication improve, the parents stress levels go down.
This study goes on to say that oils made from the cannabis plant helped tremendously with autism spectrum disorder symptoms:
- Behavioral outbreaks were much improved or very much improved (on the CGIC scale) in 61% of patients.
- The anxiety and communication problems were much or very much improved in 39% and 47% respectively.
- Disruptive behaviors, were improved by 29% from 4.74±1.82 as recorded at baseline on the HSQ-ASD to 3.36±1.56 following the treatment.
- Parents reported less stress as reflected in the APSI scores, changing by 33% from 2.04±0.77 to 1.37±0.59
April 10, 2018; 90 (15 Supplement) APRIL 24, 2018
Cannabidiol Based Medical Cannabis in Children with Autism- a Retrospective Feasibility Study (P3.318)
ADI ARAN, Hanoch Cassuto and Asael Lubotzky
First published April 9, 2018,
Objective: This retrospective study assessed safety, tolerability and efficacy of cannabidiol (CBD) based medical cannabis, as an adjuvant therapy, for refractory behavioral problems in children with ASD.
Background: Anecdotal evidence of successful cannabis treatment in children with autism spectrum disorder (ASD) are accumulating but formal studies are lacking.
Design/Methods: Sixty children with ASD (age = 11.8± 3.5, range 5.0–17.5; 77% low functioning; 83% boys) were treated with oral CBD and tetrahydrocannabinol (THC) at a ratio of 20:1. The dose was up-titrated to effect (maximal CBD dose − 10mg/kg/d). Tolerability and efficacy were assessed using a modified Liverpool Adverse Events Profile, the Caregiver Global Impression of Change (CGIC) scale, the Home Situations Questionnaire–Autism Spectrum Disorder (HSQ-ASD) and the Autism Parenting Stress Index (APSI).
Results: Following the cannabis treatment, behavioral outbreaks were much improved or very much improved (on the CGIC scale) in 61% of patients. The anxiety and communication problems were much or very much improved in 39% and 47% respectively. Disruptive behaviors, were improved by 29% from 4.74±1.82 as recorded at baseline on the HSQ-ASD to 3.36±1.56 following the treatment. Parents reported less stress as reflected in the APSI scores, changing by 33% from 2.04±0.77 to 1.37±0.59. The effect on all outcome measures was more apparent in boys with non-syndromic ASD. Adverse events included sleep disturbances (14%) irritability (9%) and loss of appetite (9%).
Conclusions: This preliminary study support the feasibility of CBD based medical cannabis as a promising treatment option for refractory behavioral problems in children with ASD. Based on these promising results, we have launched a large, double blind, placebo controlled cross-over trial with 120 participants (NCT02956226).